The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.e

Pneumocystis jiroveci pneumonia

Publications

De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, van Herpen CM

Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.

Critical reviews in oncology/hematology. 2013;85(3):373-82

Hayashi H, Saito Y, Kokuho N, Morimoto T, Kobayashi K, Tanaka T, Abe S, Fujita K, Azuma A, Gemma A

Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma.

Japanese journal of clinical oncology. 2012;42(7):632-6

Yu SK, Chalmers AJ

Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia.

Clinical oncology (Royal College of Radiologists (Great Britain)). 2007;19(8):631-2